New Low-Dose combo after transplant aims to stop leukemia relapse
NCT ID NCT06129734
First seen Apr 28, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a stem cell transplant can prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 20 participants will receive the treatment for up to one year, alongside standard post-transplant care. The main goals are to see if the approach is safe and feasible, and whether it helps control any remaining cancer cells with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospitals Seidman Cancer, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.